Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bruker and Erasmus Medical Center Sign an Exclusive Licensing Agreement

Published: Friday, January 04, 2013
Last Updated: Friday, January 04, 2013
Bookmark and Share
Agreement for adding rapid beta-lactamase testing capabilities to the MALDI Biotyper system.

Bruker has announced an exclusive licensing agreement with Erasmus Medical Center, Rotterdam, The Netherlands for rapid testing of beta-lactamase activity using MALDI-TOF technology.

This new method is fully compatible with the well-established Bruker MALDI Biotyper system, which is used for MALDI-TOF mass spectrometry-based identification of microorganisms in over 700 clinical and non-clinical microbiology laboratories worldwide.

In many laboratories, the MALDI Biotyper has replaced classical biochemical testing for bacterial identification in the past five years due to the accuracy, speed, extensive species coverage, ease of use and cost effectiveness of the system.

Classical biochemical techniques depend upon detecting different metabolic properties of microorganisms; however, these techniques can take hours or even days for completion and they lack specificity.

The MALDI Biotyper uses a molecular approach based on specific proteomic fingerprints from bacterial and fungal strains and published studies have highlighted the greater accuracy offered, as well as the typically much faster time-to-result (TTR).

With an installed base of more than 700 MALDI Biotyper systems at the end of 2012, Bruker estimates that in the year 2012 its customers performed about 20 million microbial identifications on the MALDI Biotyper installed base.

In addition to this paradigm shift for microbial identification, the MALDI Biotyper is increasingly being used for functional resistance mechanism detection.

Antibiotic resistance is an ever increasing problem as bacteria acquire new mechanisms of resistance against classes of antibiotics currently being used in clinical care.

Data from the WHO European Region shows that resistance of some pathogens now reaches over 50% in some countries, and new resistance mechanisms are emerging and spreading rapidly.

In the European Union, Norway and Iceland it is estimated that 400,000 resistant infections are occurring every year, leading to approximately 25,000 deaths.

Gram-negative bacteria are a common source of infections and pose significant challenges due to their ability to rapidly acquire new resistance mechanisms resulting in multi-drug resistant (MDR) strains.

One such mechanism of resistance found in gram-negatives is Extended Spectrum Beta-Lactamase (ESBL) in which enzymes produced by bacteria attack and cleave the beta-lactam ring in antibiotics, thus rendering them ineffective. This includes penicillins, and third generation cephalosporins.

Another mechanism is resistance to Carbapenems, which frequently are the drugs of last resort for clinicians when other antibiotics have been ineffective due to resistance.

Consumption of carbapenems increased significantly in European countries from 2007-2010 and occurrence of carbapenem-resistant Klebsiella pneumonia is already high and increasing in some European countries.

Recent publications in both the scientific and popular press have high-lighted the challenge and outbreaks associated with microorganisms containing ESBL mechanisms including reports on NDM-1, KPC and most recently CRE (Carbapenem-Resistant Enterobacteriaceae).

Accurate and rapid detection of resistance is essential for effective infection control measures, as current techniques lack either specificity or rapid turn-around time.

MALDI-TOF mass spectrometry allows for an exact determination of the molecular weight of a broad range of antibiotics. In the presence of an ESBL, the antibiotic is converted to fragments of predictable molecular weight which are also measured using the MALDI Biotyper.

As with bacterial identification, the MALDI Biotyper is thus anticipated to provide both improved, shorter time-to-result as well as potentially better specificity.

Dr. Theo Luider, Head of the Laboratories of Neuro-Oncology, Department of Neurology, Erasmus University of Rotterdam, pointed out: “We have been working with MALDI-TOF mass spectrometry for many years originally in the field of clinical proteomics, but more recently the increased usage of the MALDI-TOF approach for microbial identification also became an area of interest for us. We have filed a PCT patent for the characterization of beta-lactamase activity by MALDI-TOF mass spectrometry with the title "Methods and means for characterizing antibiotic resistance in microorganisms". With their outstanding expertise in mass spectrometry and clinical microbiology market presence, we think that Bruker is the right partner to bring such novel assays to the market.”

Dr. Stefan Zimmermann, Department of Infectious Disease, Medical Microbiology and Hygiene,at the University Hospital Heidelberg, commented: “We have been using MALDI Biotyper-based functional beta-lactamase assays in our hospital for roughly two years with the main application being epidemiology and hospital hygiene. It is of great importance to know as early as possible, especially in the intensive care unit, if a new patient carries a carbapenem-resistant Klebsiella pneumonia (KPC). In this case we are able to isolate the patient sooner than with older phenotypic methods. MALDI Biotyper-based KPC-testing improves patient health and at the same time improves cost-efficiency of the Intensive Care Unit by limiting the isolation of patients to those cases where it is really necessary.”

Dr. Wolfgang Pusch, Executive Vice President - Microbiology Business at Bruker Daltonics, added: “The signing of this exclusive license agreement with the Erasmus Medical Center is another major milestone in our MALDI Biotyper strategy. While MALDI Biotyper-based microbial identification is already established in many countries, we see significant growth potential in MALDI-based beta-lactamase testing. The exclusively licensed IP from Erasmus Medical Center further strengthens our own broad portfolio of intellectual property in the field of mass spectrometry-based microbial analysis ranging from sample preparation, data processing, MALDI-TOF technology, direct analysis from positive blood cultures and beta-lactamase testing, and offers laboratories worldwide another tool in the fight against resistant bacteria.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker and SISCAPA Assay Technologies Announce Second-Phase Collaboration Agreement
The ongoing collaboration aims to exploit MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.
Monday, September 16, 2013
Bruker and 3M Sign Exclusive Patent License Agreement
The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin.
Tuesday, June 04, 2013
Bruker and SCiLS GmbH Announce an Exclusive Partnership
SCiLS Lab is the software developed by SCiLS GmbH which allows the user-friendly statistical analysis of large MALDI imaging datasets.
Wednesday, May 15, 2013
Bruker and the Genome British Columbia Proteomics Centre to Collaborate
The collaborative effort covers the development and validation of high-throughput assays for determining hemoglobin variants and diabetes risk.
Thursday, April 18, 2013
Bruker and JMI Laboratories Announce Collaboration for Mass Spectrometry
The collaboration sees Bruker and JMI Laboratories partner in the field of fungal identification by proteomics fingerprinting.
Wednesday, June 20, 2012
Bruker and SAT Announce Joint Publication
Publication of study on SISCAPA-MALDI-TOF mass spectrometry for biomarker validation and clinical research.
Monday, April 23, 2012
Bruker and Berkeley Lab Collaborate on Novel Technology for Structural Biology
Berkeley Lab and Bruker intend to integrate SAXS and NMR data for 3D structure determination of multi-domain proteins and protein complexes with DNA, RNA or other proteins.
Thursday, November 24, 2011
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos